RGT-490 for Breast Cancer

This trial tests a new oral treatment called RGT-490 to determine its safety and effectiveness for individuals with certain types of advanced cancer, including breast cancer. Researchers focus on tumors with a specific gene change, the PIK3CA mutation. The trial is divided into parts to explore different doses and effects. Suitable candidates have advanced cancer that cannot be surgically removed and have not responded to at least one other treatment. As a Phase 1 trial, the research aims to understand how the treatment works in people, offering participants the opportunity to be among the first to receive this new treatment.

The trial protocol mentions a 'washout period' (time without taking certain medications) before starting the study treatment, which suggests you may need to stop some current medications. However, it does not specify which medications, so it's best to discuss this with the trial team.

Research shows that RGT-490, the treatment under study in this trial, remains in the early testing stages. Limited information exists about its safety for humans. The primary goal of these early trials is to assess how people handle the treatment and identify any side effects. As a phase 1 trial, the focus is on determining the right dose and checking for immediate safety issues.

RGT-490 is being tested specifically for patients with advanced breast cancer that has certain genetic changes. These early trials assess how people's bodies respond to the treatment, including any possible side effects. Since it's an early phase study, participants should know that safety information is still being collected.

Most treatments for breast cancer, like chemotherapy and hormone therapy, work by targeting rapidly dividing cells or blocking hormones that fuel cancer growth. But RGT-490 stands out because it targets a specific genetic mutation, PIK3CA, which plays a key role in cancer cell growth and survival. Researchers are excited because this precision approach could offer more effective and personalized treatment for patients, potentially leading to better outcomes with fewer side effects.

Research has shown that RGT-490 targets tumors with alterations in the PI3KCA gene, a change often linked to more challenging-to-treat breast cancers. Early results suggest that targeting this alteration could slow cancer growth. In this trial, researchers are testing RGT-490 as a monotherapy in two separate arms: one for advanced solid tumors with the PIK3CA mutation and another for HR+/HER2- locally advanced or metastatic breast cancer. Although data on RGT-490's effectiveness remains limited, its approach builds on successful methods used in other PI3K-targeted treatments.¹⁶⁷⁸⁹